Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Vaccines, Standards & Regulation, Supply Chain, Trends & Forecasts, COVID-19

Comirnaty for the Community?

The Pfizer-BioNTech COVID-19 vaccine (marketed as Comirnaty) was approved by the FDA for “emergency use” last year but has now received full approval for individuals aged 16 years and over. It remains under emergency use approval for children aged 12 to 15, and for a third dose in certain immunocompromised individuals.

According to Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, “hundreds of thousands” of pages of scientific data were reviewed as part of the evaluation, including data from around 20,000 vaccine and 20,000 placebo recipients. The FDA also evaluated post-authorization safety surveillance data; the prescribing information will include a warning about the risk of myocarditis and pericarditis in certain individuals.

In a statement (1), Marks said, “The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the US.”

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. FDA (2021). Available at: https://bit.ly/3yKUEgB
About the Author
Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register